SlideShare uma empresa Scribd logo
1 de 55
Baixar para ler offline
RHEUMATOID ARTHRITIS
Dr. Gajanan Pandit
D. Ortho; DNB Ortho
DEEPAK HOSPITAL JALNA
Rheumatoid Arthritis:
Key Features
• Symptoms >6 weeks’ duration
• Often lasts the remainder of the patient’s life
• Inflammatory synovitis
• Palpable synovial swelling
• Morning stiffness >1 hour, fatigue
• Symmetrical and polyarticular (>3 joints)
• Typically involves wrists, MCP, and PIP joints
• Typically spares certain joints
• Thoracolumbar spine
• DIPs of the fingers and IPs of the toes
Rheumatoid Arthritis:
Key Features (cont’d)
• May have nodules: subcutaneous or periosteal at
pressure points
• Rheumatoid factor
• 45% positive in first 6 months
• 85% positive with established disease
• Not specific for RA, high titer early is a bad
sign
• Marginal erosions and joint space narrowing on
x-ray
Adapted from Arnett, et al. Arth Rheum. 1988;31:315–324.
Rheumatoid Arthritis: PIP Swelling
 Swelling is confined to
the area of the joint
capsule
 Synovial thickening
feels like a firm
sponge
Rheumatoid Arthritis:
Ulnar Deviation and MCP Swelling
 An across-the-room
diagnosis
 Prominent ulnar
deviation in the right
hand
 MCP and PIP swelling
in both hands
 Synovitis of left wrist
Clinical Course of RA
Type 1 = Self-limited—5% to 20%
Type 2 = Minimally progressive—5% to 20%
Type 3 = Progressive—60% to 90%
0
1
2
3
4
0 0.5 1 2 3 4 6 8 16
Type 1
Type 2
Type 3
Years
SeverityofArthritis
Pincus. Rheum Dis Clin North Am. 1995;21:619.
Pincus, et al. Rheum Dis Clin North Am. 1993;19:123–151.
Rheumatoid Arthritis: Typical Course
• Damage occurs early in most patients
• 50% show joint space narrowing or erosions in
the first 2 years
• By 10 years, 50% of young working patients
are disabled
• Death comes early
• Multiple causes
• Compared to general population
• Women lose 10 years, men lose 4 years
Rheumatoid Arthritis
• Key points:
• The sicker they are and the faster they get that
way, the worse the future will be
• Early intervention can make a difference
• Essential to establish a treatment plan early in
the disease
Rheumatoid Arthritis:
Treatment Principles
 Confirm the diagnosis
 Determine where the patient stands in the
spectrum of disease
 When damage begins early, start aggressive
treatment early
 Use the safest treatment plan that matches the
aggressiveness of the disease
 Monitor treatment for adverse effects
 Monitor disease activity, revise Rx as needed
Critical Elements of a Treatment Plan:
Assessment
• Assess current activity
• Morning stiffness, synovitis, fatigue, ESR
• Document the degree of damage
• ROM and deformities
• Joint space narrowing and erosions on x-ray
• Functional status
• Document extra-articular manifestations
• Nodules, pulmonary fibrosis, vasculitis
• Assess prior Rx responses and side effects
Critical Elements of a Treatment Plan:
Therapy
• Education
• Build a cooperative long-term relationship
• Assistive devices
• Exercise
• ROM, conditioning, and strengthening exercises
• Medications
• Analgesic and/or anti-inflammatory
• Immunosuppressive, cytotoxic, and biologic
• Balance efficacy and safety with activity
Rheumatoid Arthritis:
Drug Treatment Options
• NSAIDs
• Symptomatic relief, improved function
• No change in disease progression
• Low-dose prednisone (10 mg qd)
• May substitute for NSAID
• Used as bridge therapy
• If used long term, consider prophylactic
treatment for osteoporosis
• Intra-articular steroids
• Useful for flares
Paget. Primer on Rheum Dis. 11th edition. 1997:168.
Rheumatoid Arthritis:
Treatment Options
• Disease modifying drugs (DMARDs)
• Minocycline
• Modest effect, may work best early
• Sulfasalazine, hydroxychloroquine
• Moderate effect, low cost
• Intramuscular gold
• Slow onset, decreases progression, rare
remission
• Requires close monitoring
Alarcon. Rheum Dis Clin North Am. 1998;24:489–499.
Paget. Primer on Rheum Dis. 11th edition. 1997:168.
Paget. Primer on Rheum Dis. 11th edition. 1997:168.
Rheumatoid Arthritis:
Treatment Options (cont’d)
• Immunosuppressive drugs
• Methotrexate
• Most effective single DMARD
• Good benefit-to-risk ratio
• Azathioprine
• Slow onset, reasonably effective
• Cyclophosphamide
• Effective for vasculitis, less so for arthritis
• Cyclosporine
• Superior to placebo, renal toxicity
Rheumatoid Arthritis: Treatment
New Options—Combinations
 Methotrexate,
hydroxychloroquine,
and sulfasalazine
 Superior to any one or
two alone for ACR
50% improvement
response and
maintenance of the
response
 Side effects no greater0
10
20
30
40
50
60
70
80
90
2-Year Outcome
PercentWith50%ACRResponse
Triple
RX
SSZ+
HCQ
MTX
Rheumatoid Arthritis: Treatment
New Options—Combinations (cont’d)
• Step-down prednisone with sulfasalazine and
low-dose methotrexate*
• Superior to sulfasalazine in early disease*
• Methotrexate + hydroxychloroquine or
methotrexate + cyclosporine†
• May have additive beneficial effects†
*Boers, et al. Lancet. 1997;350:309–318.
†Stein, et al. Arth Rheum. 1997;40:1721–1723.
Rheumatoid Arthritis: Treatment
Options—New DMARDs
• Leflunomide
• Pyrimidine inhibitor
• Effect and side effects similar to those of MTX
• Etanercept
• Soluble TNF receptor, blocks TNF
• Rapid onset, quite effective in refractory
patients in short-term trials and in combination
with MTX
• Injection site reactions, long-term effects
unknown, expensive
Rozman. J Rheumatol. 1998;53:27–32.
Moreland. Rheum Dis Clin North Am. 1998;24:579–591.
Rheumatoid Arthritis: Monitoring
Treatment With DMARDs
• These drugs need frequent monitoring
• Blood, liver, lung, and kidney are frequent sites of
adverse effects
• Interval of laboratory testing varies with the drug
• 4- to 8-week intervals are commonly needed
• Most patients need to be seen 3 to 6 times a year
Rheumatoid Arthritis:
Adverse Effects of DMARDs
Drug Hem Liver Lung Renal Infect Ca Other
HCQ + - - - - - Eye
SSZ + + + - - - GI Sx
Gold ++ - + ++ - - Rash
MTX + + ++ - ++ ? Mucositis
AZA ++ + - - ++ + Pancreas
PcN ++ + + ++ - - SLE, MG
Cy +++ - - - +++ +++ Cystitis
CSA + ++ - +++ ++ + HTN
TNF* - - - - ? ? Local
Lef* ++ ++ - - ? ?
*Long-term data not available.
Adapted from Paget. Primer on Rheum Dis. 11th edition. 1997:168.
Rheumatoid Arthritis
Case Management
Rheumatoid Arthritis: Case 1
 34-year-old woman with 5-year history of RA
 Morning stiffness = 30 minutes
 Synovitis: 1+ swelling of MCP, PIP, wrist, and
MTP joints
 Normal joint alignment
 Rheumatoid factor positive
 No erosions seen on x-rays
Rheumatoid Arthritis: Case 1 (cont’d)
• Assessment
• Current activity—mild
• No sign of damage after 5 years
• Type 2 minimally progressive course
• Treatment
• NSAID + safer, less potent drugs, eg,
• Hydroxychloroquine, minocycline, or
sulfasalazine
• Education + ROM, conditioning, and
strengthening exercises
Rheumatoid Arthritis: Case 2
 34-year-old woman with 1-year history of RA
 Morning stiffness = 90 minutes
 Synovitis: 1+ to 2+ swelling of MCP, PIP, wrist,
knee, and MTP joints
 Normal joint alignment
 RF positive
 Small erosions of the right wrist and two MCP
joints seen on x-rays
Rheumatoid Arthritis: Case 2 (cont’d)
Early erosion at the tip of the ulnar styloid
A. Soft-tissue swelling,
no erosions
B. Thinning of the cortex
on the radial side and
minimal joint space
narrowing
C. Marginal erosion at
the radial side of the
metacarpal head with
joint space narrowing
How fast is joint damage progressing?
Rheumatoid Arthritis: Case 2 (cont’d)
ACR Clinical Slide Collection, 1997.
Rheumatoid Arthritis: Case 2 (cont’d)
• Assessment of case 2
• Moderate disease activity
• Many joints involved
• Clear radiologic signs of joint destruction early
in disease course
• Type 3 progressive course
• Treatment should be more aggressive
• NSAID, MTX, SSZ, and hydroxychloroquine
would be a good choice
Rheumatoid Arthritis: Case 3
• 34-year-old woman with 3-year history of RA
• Morning stiffness = 3 hours
• 2 to 3+ swelling of MCP, PIP, wrist, elbow,
knee, and MTP joints
• Ulnar deviation, swan neck deformities,
decreased ROM at wrists, nodules on elbows
• RF positive, x-rays show erosions of wrists and
MCP joints bilaterally
• Currently on low-dose prednisone + MTX, SSZ,
and hydroxychloroquine
Rheumatoid Arthritis: Case 3 (cont’d)
• Assessment
• Very active disease in spite of aggressive
combination therapy
• Evidence of extensive joint destruction
• Treatment options are many
• Step-down oral prednisone, 60 mg qd tapered
to 10 mg qd over 5 weeks, can be used for
immediate relief of symptoms
• Use other cytotoxics or cyclosporine
• Consider TNF inhibitor or leflunomide
Rheumatoid Arthritis:
Treatment Plan Summary
• A variety of treatment options are available
• Treatment plan should match
• The current disease activity
• The documented and anticipated pace of joint
destruction
• Consider a rheumatology consult to help design a
treatment plan
Rheumatoid Arthritis
Potential Complications
RA: Unknown Case 1
 68-year-old woman with 3-year history of RA is
squeezed into your schedule as a new patient
 She presents with 4 weeks of increasing fatigue,
dizziness, dyspnea, and anorexia
 Her joint pain and stiffness are mild and
unchanged
 Managed with ibuprofen and hydroxychloroquine
until 4 months ago, when a flare caused a switch
to piroxicam and prednisone
RA: Unknown Case 1 (cont’d)
 Past history: Peptic ulcer 10 years ago and mild
hypertension
 Exam shows a thin, pale apathetic woman with
Temp 98.4ºF, BP 110/65, pulse 110 bpm
 Symmetrical 1+ synovitis of the wrist, MCP, PIP,
and MTP joints
 Exam of the heart, lungs, and abdomen is
unremarkable
RA: Unknown Case 1 (cont’d)
 You are falling behind in your schedule
 What system must you inquire more
about today?
A. Cardiovascular
B. Neuropsychological
C. Endocrine
D. Gastrointestinal
RA: Unknown Case 1 (cont’d)
Don’t
Miss It
• NSAID Gastropathy
is sneaky and can be
fatal
RA: Unknown Case 1 (cont’d)
• Clues of impending disaster
• High risk for NSAID gastropathy
• Presentation suggestive of blood loss
• Pale, dizzy, weak
• Tachycardia, low blood pressure
• No evidence of flare in RA to explain recent
symptoms of increased fatigue
Singh. Am J Med. 1998;105(suppl B):31S–38S.
NSAID Gastropathy
 Gastric ulcers > duodenal ulcers
 No reliable warning signs
 80% of serious events occur without prior
symptoms
 Risk of hospitalization for NSAID ulcers in RA is
2.5 to 5.5 times higher than general population
Singh. Am J Med. 1998;105(suppl B):31S–38S.
Key Point: Know the Risk Factors
for NSAID Ulcers
 Older age
 Prior history of peptic ulcer or GI symptoms with
NSAIDs
 Concomitant use of prednisone
 NSAID dose: More prostaglandin suppression =
greater risk of serious events
 Disability level: The sicker the patient the higher
the risk
Hawkey. N Engl J Med. 1998;338:727–734.
NSAID Gastropathy: Treatment
• Acute bleed or perforation
• Stop NSAID
• Endoscopy or surgery
• Start omeprazole
• Ulcer without bleed or perforation, and needs or
wants continued NSAID
• Omeprazole 20 mg qd—76% healed
• Misoprostol 200 µg qid—71% healed
NSAID Gastropathy: Prevention
• Avoid the problem
• Stop the NSAID and use alternative treatment
• Low-dose prednisone
• Acetaminophen
• Nonacetylated salicylates
• Use a selective cyclooxygenase-2 inhibitor
Differential Expression of COX-1 and COX-2
Cyclooxygenase (COX) enzymes are a key step in
prostaglandin production
COX-1
Housekeeping
most tissues
stomach
platelets
kidney
Inducible
macrophages
Furst. Rheum Grand Rounds. 1998;1:1.
Needleman, et al. J Rheumatol. 1997;24(suppl 49):6–8.
COX-2
Inducible
immune system,
ovary, amniotic fluid,
bone, kidney,
colorectal tumors
Housekeeping
brain, kidney
Selective COX-2 Suppression:
A Potentially Elegant Solution
• Traditional NSAIDs at full therapeutic doses inhibit
both enzymes
• Most have greater effect on COX-1 than COX-2
• The new drugs are highly selective for COX-2
• >300-fold more effective against COX-2
• This difference allows
• Major reduction in COX-2 production of
proinflammatory PGs
• Sparing of COX-1–produced housekeeping
PGs
Vane, Botting. Am J Med. 1998;104(suppl 3A):2S–8S.
NSAID Gastropathy: Prevention
• Short-term (1 to 4 weeks) clinical studies with
COX-2 inhibitor in patients with OA and RA*
• Significant control of arthritis symptoms
• Fewer endoscopic ulcers
• No effect on platelet aggregation or
bleeding time
• Insufficient data to determine risk of serious
events or safety in high-risk populations
• Celecoxib and rofecoxib have been approved;
meloxicam and other selective inhibitors are
currently in clinical trials
*Celecoxib.
Simon, et al. Arth Rheum. 1998;41:1591–1602.
NSAID Gastropathy: Prevention (cont’d)
• Counteract the problem
• Misoprostol
• Reduction of serious events by 40%
• Results best with 200 µg qid
• Side effects: diarrhea and uterine cramps
• Avoid if pregnancy risk is present
• Omeprazole
• Recent studies show 72% to 78% reduction in
all ulcers when used for primary prevention at
20 mg qd
Scheiman, Isenberg. Am J Med. 1998;105(suppl 5A):32S–38S.
Hawkey. Am J Med. 1998;104(suppl 3A):67S–74S.
NSAID Gastropathy: Key Points
• Keep it in mind
• Know the risk factors
• The best way to treat it is to prevent it
• Avoid it: Use acetaminophen, salsalate, or a
selective COX-2 inhibitor
• Counteract it: Omeprazole or misoprostol
• Antacids and H2 blockers are not the answer
• May mask symptoms but do not prevent
serious events
Rheumatoid Arthritis: Unknown Case 2
 You are doing a preop physical for a routine
cholecystectomy on a 43-year-old woman with
RA since age 20. PH includes bilateral THAs and
left TKA. No other medical problems. Current
meds: NSAID, low-dose prednisone, MTX, and
HCQ
 General physical exam normal
 MS exam, extensive deformities, mild synovitis
 In addition to routine tests, what test should be
ordered before surgery?
Don’t Miss It
Subluxation of C1 on C2
RA can cause asymptomatic instability of the neck
Manipulation under anesthesia can cause spinal cord injury
Clues for C1-C2 Subluxation
• Long-standing rheumatoid arthritis or JRA
• May have NO symptoms
• C2-C3 radicular pain in the neck and occiput
• Spinal cord compression
• Quadriparesis or paraparesis
• Sphincter dysfunction
• Sensory deficits
• TIAs secondary to compromise of the vertebral
arteries
Anderson. Primer on Rheum Dis. 11th edition. 1997:161.
Rheumatoid Arthritis:
Special Considerations on Preop Exam
• C1-C2 subluxation
• Cricoarytenoid arthritis with adductor spasm of
the vocal cords and a narrow airway
• Pulmonary fibrosis
• Risk for GI bleeding
• Need for stress steroid coverage
• Discontinue NSAIDs several days preop
• Discontinue methotrexate 1 to 2 weeks preop
• Cover with analgesic meds or if necessary
short-term, low-dose steroid if RA flares
Rheumatoid Arthritis: Unknown Case 3
 52-year-old man with destructive RA treated with
NSAID and low-dose prednisone. MTX started 4
months ago, now 15 mg/wk
 Presents with 3-week history of fever, dry cough,
and increasing shortness of breath
 Exam: Low-grade fever, fine rales in both lungs,
normal CBC and liver enzymes, low albumin,
diffuse interstitial infiltrates on chest x-ray
RA: Unknown Case 3 (cont’d)
 What would you do?
A. Culture, treat with antibiotic for bacterial
pneumonia
B. Culture, give cough suppressant for viral
pneumonia and watch
C. Give oral steroid for hypersensitivity
pneumonitis and stop methotrexate
D. Give a high-dose oral pulse of steroid
and increase methotrexate for
rheumatoid lung
DMARDs Have a Dark Side
Don’t Miss It
DMARDs have a dark side
Methotrexate may cause
serious problems
Lung
Liver
Bone marrow
Be on the look out for toxicity
with all the DMARDs
Methotrexate Lung
• Dry cough, shortness of breath, fever
• Most often seen in the first 6 months of MTX
treatment
• Diffuse interstitial pattern on x-ray
• Bronchoalveolar lavage may be needed to rule
out infection
• Acute mortality = 17%; 50% to 60% recur with
retreatment, which carries the same mortality
• Risk factors: older age, RA lung, prior use of
DMARD, low albumin, diabetes
Kremer, et al. Arth Rheum. 1997;40:1829–1837.
Rheumatoid Arthritis: Summary
• Joint damage begins early
• Effective treatment should begin early in most
patients
• Aggressive treatment can make a difference
• Assess severity of patient’s disease
• Current activity
• Damage
• Pace
Rheumatoid Arthritis: Summary (cont’d)
• Choose a treatment plan with enough power to
match the disease
• If in doubt, get some help
• Rheumatologists can be a bargain
• New classes of drugs and biologics offer new
opportunities
• Do no harm
• Monitor for drug toxicity—high index of
suspicion and routine monitoring
• Alter the treatment based on changes in
disease activity
Thank You…

Mais conteúdo relacionado

Mais procurados

Mais procurados (20)

Gout and pseudogout
Gout and pseudogoutGout and pseudogout
Gout and pseudogout
 
Crystal associated arthropathies
Crystal associated arthropathiesCrystal associated arthropathies
Crystal associated arthropathies
 
Osteoarthritis
OsteoarthritisOsteoarthritis
Osteoarthritis
 
Psoriatic arthritis
Psoriatic arthritis Psoriatic arthritis
Psoriatic arthritis
 
Spondyloarthropathy
SpondyloarthropathySpondyloarthropathy
Spondyloarthropathy
 
Trigger finger final
Trigger finger finalTrigger finger final
Trigger finger final
 
Rheumatois arthritis , pain management..
Rheumatois arthritis , pain management..Rheumatois arthritis , pain management..
Rheumatois arthritis , pain management..
 
Rheumatoid arthritis
Rheumatoid arthritisRheumatoid arthritis
Rheumatoid arthritis
 
Osteoarthritis general
Osteoarthritis generalOsteoarthritis general
Osteoarthritis general
 
Ankylosing Spondylitis
Ankylosing SpondylitisAnkylosing Spondylitis
Ankylosing Spondylitis
 
Ankylosing spondylitis
Ankylosing spondylitisAnkylosing spondylitis
Ankylosing spondylitis
 
Osteoarthritis
OsteoarthritisOsteoarthritis
Osteoarthritis
 
Rheumatoid arthritis
Rheumatoid arthritisRheumatoid arthritis
Rheumatoid arthritis
 
rheumatoid arthritis
rheumatoid arthritisrheumatoid arthritis
rheumatoid arthritis
 
Rheumatoid arthritis
Rheumatoid arthritisRheumatoid arthritis
Rheumatoid arthritis
 
Management of Osteoarthritis
Management of OsteoarthritisManagement of Osteoarthritis
Management of Osteoarthritis
 
Seronegative arthropathies
Seronegative arthropathiesSeronegative arthropathies
Seronegative arthropathies
 
Rheumatoid arthritis current diagnosis and treatment
Rheumatoid arthritis current diagnosis and treatmentRheumatoid arthritis current diagnosis and treatment
Rheumatoid arthritis current diagnosis and treatment
 
Crystal arthropathies gout & pseudogout
Crystal arthropathies  gout & pseudogoutCrystal arthropathies  gout & pseudogout
Crystal arthropathies gout & pseudogout
 
4 Rheumatoid Arthriis 2010
4 Rheumatoid Arthriis 20104 Rheumatoid Arthriis 2010
4 Rheumatoid Arthriis 2010
 

Semelhante a Rheumatoid Arthritis

3 evaluation and management of rheumatoid arthritis
3 evaluation and management of rheumatoid arthritis3 evaluation and management of rheumatoid arthritis
3 evaluation and management of rheumatoid arthritisAmer
 
Chris Deighton
Chris DeightonChris Deighton
Chris Deightonacare
 
Potts spine management part 2
Potts spine management part 2Potts spine management part 2
Potts spine management part 2Arjun Kouloth
 
BIOLOGICS IN RHEUMATOID ARTHRITIS
BIOLOGICS IN RHEUMATOID ARTHRITISBIOLOGICS IN RHEUMATOID ARTHRITIS
BIOLOGICS IN RHEUMATOID ARTHRITISDr. Sachin Kumar
 
4_Evaluation and Management of Osteoarthritis.ppt
4_Evaluation and Management of Osteoarthritis.ppt4_Evaluation and Management of Osteoarthritis.ppt
4_Evaluation and Management of Osteoarthritis.pptbiruktesfaye27
 
Evaluation and Management of Osteoarthritis (2).ppt
Evaluation and Management of Osteoarthritis (2).pptEvaluation and Management of Osteoarthritis (2).ppt
Evaluation and Management of Osteoarthritis (2).pptbiruktesfaye27
 
Rheumatoid Arthritis Pathology, C/F and Diagnosis and Mx.ppt
Rheumatoid Arthritis Pathology, C/F and Diagnosis and Mx.pptRheumatoid Arthritis Pathology, C/F and Diagnosis and Mx.ppt
Rheumatoid Arthritis Pathology, C/F and Diagnosis and Mx.pptBharath Kal
 
Interventional Techniques For Cancer Pain Management.
Interventional Techniques For Cancer Pain Management.Interventional Techniques For Cancer Pain Management.
Interventional Techniques For Cancer Pain Management.guest7342323
 
Management of rheumatoid arthritis
Management of rheumatoid arthritisManagement of rheumatoid arthritis
Management of rheumatoid arthritisAsi-oqua Bassey
 
Recent advances in crps (Physiotherapy perspective)
Recent advances in crps (Physiotherapy perspective)Recent advances in crps (Physiotherapy perspective)
Recent advances in crps (Physiotherapy perspective)Siddharth Bagrecha
 
Rheumatic Diseases | Rheumatoid Arthritis
Rheumatic Diseases | Rheumatoid ArthritisRheumatic Diseases | Rheumatoid Arthritis
Rheumatic Diseases | Rheumatoid ArthritisSubhash Thakur
 
rheumatoid arthritis.ppt
rheumatoid arthritis.pptrheumatoid arthritis.ppt
rheumatoid arthritis.pptMinella4
 
Inflammatory arthritis; a quick run through.
Inflammatory arthritis; a quick run through.Inflammatory arthritis; a quick run through.
Inflammatory arthritis; a quick run through.Ronan Kavanagh
 
Advancement in treatment of ra (1)
Advancement in treatment of ra (1)Advancement in treatment of ra (1)
Advancement in treatment of ra (1)Naveen Kumar
 

Semelhante a Rheumatoid Arthritis (20)

3 evaluation and management of rheumatoid arthritis
3 evaluation and management of rheumatoid arthritis3 evaluation and management of rheumatoid arthritis
3 evaluation and management of rheumatoid arthritis
 
Ra and oa residents
Ra and oa residentsRa and oa residents
Ra and oa residents
 
Chris Deighton
Chris DeightonChris Deighton
Chris Deighton
 
Potts spine management part 2
Potts spine management part 2Potts spine management part 2
Potts spine management part 2
 
Ra conference may 2017
Ra conference may 2017Ra conference may 2017
Ra conference may 2017
 
BIOLOGICS IN RHEUMATOID ARTHRITIS
BIOLOGICS IN RHEUMATOID ARTHRITISBIOLOGICS IN RHEUMATOID ARTHRITIS
BIOLOGICS IN RHEUMATOID ARTHRITIS
 
4_Evaluation and Management of Osteoarthritis.ppt
4_Evaluation and Management of Osteoarthritis.ppt4_Evaluation and Management of Osteoarthritis.ppt
4_Evaluation and Management of Osteoarthritis.ppt
 
Evaluation and Management of Osteoarthritis (2).ppt
Evaluation and Management of Osteoarthritis (2).pptEvaluation and Management of Osteoarthritis (2).ppt
Evaluation and Management of Osteoarthritis (2).ppt
 
Rheumatoid Arthritis Pathology, C/F and Diagnosis and Mx.ppt
Rheumatoid Arthritis Pathology, C/F and Diagnosis and Mx.pptRheumatoid Arthritis Pathology, C/F and Diagnosis and Mx.ppt
Rheumatoid Arthritis Pathology, C/F and Diagnosis and Mx.ppt
 
Interventional Techniques For Cancer Pain Management.
Interventional Techniques For Cancer Pain Management.Interventional Techniques For Cancer Pain Management.
Interventional Techniques For Cancer Pain Management.
 
Management of rheumatoid arthritis
Management of rheumatoid arthritisManagement of rheumatoid arthritis
Management of rheumatoid arthritis
 
M2 artritis de reciente inicio
M2 artritis de reciente inicioM2 artritis de reciente inicio
M2 artritis de reciente inicio
 
Complex Regional pain syndrome
Complex Regional pain syndromeComplex Regional pain syndrome
Complex Regional pain syndrome
 
Recent advances in crps (Physiotherapy perspective)
Recent advances in crps (Physiotherapy perspective)Recent advances in crps (Physiotherapy perspective)
Recent advances in crps (Physiotherapy perspective)
 
Use of Steroid in Rheumatology
Use of Steroid in RheumatologyUse of Steroid in Rheumatology
Use of Steroid in Rheumatology
 
Rheumatic Diseases | Rheumatoid Arthritis
Rheumatic Diseases | Rheumatoid ArthritisRheumatic Diseases | Rheumatoid Arthritis
Rheumatic Diseases | Rheumatoid Arthritis
 
rheumatoid arthritis.ppt
rheumatoid arthritis.pptrheumatoid arthritis.ppt
rheumatoid arthritis.ppt
 
Inflammatory arthritis; a quick run through.
Inflammatory arthritis; a quick run through.Inflammatory arthritis; a quick run through.
Inflammatory arthritis; a quick run through.
 
Advancement in treatment of ra (1)
Advancement in treatment of ra (1)Advancement in treatment of ra (1)
Advancement in treatment of ra (1)
 
Rheumatoid arthritis
Rheumatoid arthritisRheumatoid arthritis
Rheumatoid arthritis
 

Mais de Gajanan Pandit (20)

Understanding Your Body: Adolescent Girls
Understanding Your Body: Adolescent GirlsUnderstanding Your Body: Adolescent Girls
Understanding Your Body: Adolescent Girls
 
Copper
CopperCopper
Copper
 
Cobalt
CobaltCobalt
Cobalt
 
Chromium
ChromiumChromium
Chromium
 
Chlorine
ChlorineChlorine
Chlorine
 
Chemical asphyxiants
Chemical asphyxiantsChemical asphyxiants
Chemical asphyxiants
 
Chemical agents gases
Chemical agents   gasesChemical agents   gases
Chemical agents gases
 
Carbon di sulphide
Carbon di sulphideCarbon di sulphide
Carbon di sulphide
 
Cadmium
CadmiumCadmium
Cadmium
 
Biological hazards Anthrax & Amp; Brucellosis
Biological hazards  Anthrax & Amp; BrucellosisBiological hazards  Anthrax & Amp; Brucellosis
Biological hazards Anthrax & Amp; Brucellosis
 
Beryllium
BerylliumBeryllium
Beryllium
 
Benzene
BenzeneBenzene
Benzene
 
Arsenic
ArsenicArsenic
Arsenic
 
Ammonia NH3
Ammonia  NH3Ammonia  NH3
Ammonia NH3
 
Alcohol
AlcoholAlcohol
Alcohol
 
ISO 18001
ISO 18001ISO 18001
ISO 18001
 
Carpal tunnel syndrome
Carpal tunnel syndromeCarpal tunnel syndrome
Carpal tunnel syndrome
 
Hydrogen sulphide
Hydrogen sulphideHydrogen sulphide
Hydrogen sulphide
 
Major Accident Hazard Control
Major Accident Hazard ControlMajor Accident Hazard Control
Major Accident Hazard Control
 
Factors responsible for accidents & injuries
Factors responsible for accidents & injuriesFactors responsible for accidents & injuries
Factors responsible for accidents & injuries
 

Último

Diseases of the Respiratory System (J00-J99),.pptx
Diseases of the Respiratory System (J00-J99),.pptxDiseases of the Respiratory System (J00-J99),.pptx
Diseases of the Respiratory System (J00-J99),.pptxEMADABATHINI PRABHU TEJA
 
person with disability and pwd act ppt.pptx
person with disability and pwd act ppt.pptxperson with disability and pwd act ppt.pptx
person with disability and pwd act ppt.pptxMUKESH PADMANABHAN
 
Hematinics and Erythropoietin- Pharmacology of Hematinics
Hematinics and Erythropoietin- Pharmacology of HematinicsHematinics and Erythropoietin- Pharmacology of Hematinics
Hematinics and Erythropoietin- Pharmacology of Hematinicsnetraangadi2
 
Artificial Intelligence: Diabetes Management
Artificial Intelligence: Diabetes ManagementArtificial Intelligence: Diabetes Management
Artificial Intelligence: Diabetes ManagementIris Thiele Isip-Tan
 
Assisted Living Care Residency - PapayaCare
Assisted Living Care Residency - PapayaCareAssisted Living Care Residency - PapayaCare
Assisted Living Care Residency - PapayaCareratilalthakkar704
 
Identifying Signs of Mental Health Presentation (1).pptx
Identifying Signs of Mental Health Presentation (1).pptxIdentifying Signs of Mental Health Presentation (1).pptx
Identifying Signs of Mental Health Presentation (1).pptxsandhulove46637
 
Introduction to Evaluation and Skin Benefits
Introduction to Evaluation and Skin BenefitsIntroduction to Evaluation and Skin Benefits
Introduction to Evaluation and Skin Benefitssahilgabhane29
 
CECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHY
CECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHYCECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHY
CECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHYRMC
 
ACCA Version of AI & Healthcare: An Overview for the Curious
ACCA Version of AI & Healthcare: An Overview for the CuriousACCA Version of AI & Healthcare: An Overview for the Curious
ACCA Version of AI & Healthcare: An Overview for the CuriousKR_Barker
 
ARTHRITIS.pptx Prepared by monika gopal Tutor
ARTHRITIS.pptx Prepared  by monika gopal TutorARTHRITIS.pptx Prepared  by monika gopal Tutor
ARTHRITIS.pptx Prepared by monika gopal TutorNehaKewat
 
Understanding Warts and Moles: Differences, Types, and Common Locations
Understanding Warts and Moles: Differences, Types, and Common LocationsUnderstanding Warts and Moles: Differences, Types, and Common Locations
Understanding Warts and Moles: Differences, Types, and Common LocationsNeha Sharma
 
Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....
Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....
Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....sharyurangari111
 
Pharmacovigilance audits inspections.pptx
Pharmacovigilance audits inspections.pptxPharmacovigilance audits inspections.pptx
Pharmacovigilance audits inspections.pptxCliniminds India
 
Basics of Giant Cell Tumor of bone (GCTB)
Basics of Giant Cell Tumor of bone (GCTB)Basics of Giant Cell Tumor of bone (GCTB)
Basics of Giant Cell Tumor of bone (GCTB)bishwabandhuniraula
 
EYE CANCER.pptx prepared by Neha kewat digital learning
EYE CANCER.pptx prepared by  Neha kewat digital learningEYE CANCER.pptx prepared by  Neha kewat digital learning
EYE CANCER.pptx prepared by Neha kewat digital learningNehaKewat
 
FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES 11
FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES  11FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES  11
FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES 11crzljavier
 
Artificial Intelligence in Healthcare: Challenges, Risks, Benefits
Artificial Intelligence in Healthcare: Challenges, Risks, BenefitsArtificial Intelligence in Healthcare: Challenges, Risks, Benefits
Artificial Intelligence in Healthcare: Challenges, Risks, BenefitsIris Thiele Isip-Tan
 

Último (20)

SCOPE OF CRITICAL CARE ORGANIZATION
SCOPE OF CRITICAL CARE ORGANIZATIONSCOPE OF CRITICAL CARE ORGANIZATION
SCOPE OF CRITICAL CARE ORGANIZATION
 
Diseases of the Respiratory System (J00-J99),.pptx
Diseases of the Respiratory System (J00-J99),.pptxDiseases of the Respiratory System (J00-J99),.pptx
Diseases of the Respiratory System (J00-J99),.pptx
 
person with disability and pwd act ppt.pptx
person with disability and pwd act ppt.pptxperson with disability and pwd act ppt.pptx
person with disability and pwd act ppt.pptx
 
Hematinics and Erythropoietin- Pharmacology of Hematinics
Hematinics and Erythropoietin- Pharmacology of HematinicsHematinics and Erythropoietin- Pharmacology of Hematinics
Hematinics and Erythropoietin- Pharmacology of Hematinics
 
Artificial Intelligence: Diabetes Management
Artificial Intelligence: Diabetes ManagementArtificial Intelligence: Diabetes Management
Artificial Intelligence: Diabetes Management
 
Painting Rats White Angers Them to No End
Painting Rats White Angers Them to No EndPainting Rats White Angers Them to No End
Painting Rats White Angers Them to No End
 
Assisted Living Care Residency - PapayaCare
Assisted Living Care Residency - PapayaCareAssisted Living Care Residency - PapayaCare
Assisted Living Care Residency - PapayaCare
 
Identifying Signs of Mental Health Presentation (1).pptx
Identifying Signs of Mental Health Presentation (1).pptxIdentifying Signs of Mental Health Presentation (1).pptx
Identifying Signs of Mental Health Presentation (1).pptx
 
Introduction to Evaluation and Skin Benefits
Introduction to Evaluation and Skin BenefitsIntroduction to Evaluation and Skin Benefits
Introduction to Evaluation and Skin Benefits
 
CECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHY
CECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHYCECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHY
CECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHY
 
ACCA Version of AI & Healthcare: An Overview for the Curious
ACCA Version of AI & Healthcare: An Overview for the CuriousACCA Version of AI & Healthcare: An Overview for the Curious
ACCA Version of AI & Healthcare: An Overview for the Curious
 
ARTHRITIS.pptx Prepared by monika gopal Tutor
ARTHRITIS.pptx Prepared  by monika gopal TutorARTHRITIS.pptx Prepared  by monika gopal Tutor
ARTHRITIS.pptx Prepared by monika gopal Tutor
 
Understanding Warts and Moles: Differences, Types, and Common Locations
Understanding Warts and Moles: Differences, Types, and Common LocationsUnderstanding Warts and Moles: Differences, Types, and Common Locations
Understanding Warts and Moles: Differences, Types, and Common Locations
 
The Power of Active listening - Tool in effective communication.pdf
The Power of Active listening - Tool in effective communication.pdfThe Power of Active listening - Tool in effective communication.pdf
The Power of Active listening - Tool in effective communication.pdf
 
Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....
Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....
Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....
 
Pharmacovigilance audits inspections.pptx
Pharmacovigilance audits inspections.pptxPharmacovigilance audits inspections.pptx
Pharmacovigilance audits inspections.pptx
 
Basics of Giant Cell Tumor of bone (GCTB)
Basics of Giant Cell Tumor of bone (GCTB)Basics of Giant Cell Tumor of bone (GCTB)
Basics of Giant Cell Tumor of bone (GCTB)
 
EYE CANCER.pptx prepared by Neha kewat digital learning
EYE CANCER.pptx prepared by  Neha kewat digital learningEYE CANCER.pptx prepared by  Neha kewat digital learning
EYE CANCER.pptx prepared by Neha kewat digital learning
 
FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES 11
FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES  11FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES  11
FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES 11
 
Artificial Intelligence in Healthcare: Challenges, Risks, Benefits
Artificial Intelligence in Healthcare: Challenges, Risks, BenefitsArtificial Intelligence in Healthcare: Challenges, Risks, Benefits
Artificial Intelligence in Healthcare: Challenges, Risks, Benefits
 

Rheumatoid Arthritis

  • 1. RHEUMATOID ARTHRITIS Dr. Gajanan Pandit D. Ortho; DNB Ortho DEEPAK HOSPITAL JALNA
  • 2. Rheumatoid Arthritis: Key Features • Symptoms >6 weeks’ duration • Often lasts the remainder of the patient’s life • Inflammatory synovitis • Palpable synovial swelling • Morning stiffness >1 hour, fatigue • Symmetrical and polyarticular (>3 joints) • Typically involves wrists, MCP, and PIP joints • Typically spares certain joints • Thoracolumbar spine • DIPs of the fingers and IPs of the toes
  • 3. Rheumatoid Arthritis: Key Features (cont’d) • May have nodules: subcutaneous or periosteal at pressure points • Rheumatoid factor • 45% positive in first 6 months • 85% positive with established disease • Not specific for RA, high titer early is a bad sign • Marginal erosions and joint space narrowing on x-ray Adapted from Arnett, et al. Arth Rheum. 1988;31:315–324.
  • 4. Rheumatoid Arthritis: PIP Swelling  Swelling is confined to the area of the joint capsule  Synovial thickening feels like a firm sponge
  • 5. Rheumatoid Arthritis: Ulnar Deviation and MCP Swelling  An across-the-room diagnosis  Prominent ulnar deviation in the right hand  MCP and PIP swelling in both hands  Synovitis of left wrist
  • 6. Clinical Course of RA Type 1 = Self-limited—5% to 20% Type 2 = Minimally progressive—5% to 20% Type 3 = Progressive—60% to 90% 0 1 2 3 4 0 0.5 1 2 3 4 6 8 16 Type 1 Type 2 Type 3 Years SeverityofArthritis Pincus. Rheum Dis Clin North Am. 1995;21:619.
  • 7. Pincus, et al. Rheum Dis Clin North Am. 1993;19:123–151. Rheumatoid Arthritis: Typical Course • Damage occurs early in most patients • 50% show joint space narrowing or erosions in the first 2 years • By 10 years, 50% of young working patients are disabled • Death comes early • Multiple causes • Compared to general population • Women lose 10 years, men lose 4 years
  • 8. Rheumatoid Arthritis • Key points: • The sicker they are and the faster they get that way, the worse the future will be • Early intervention can make a difference • Essential to establish a treatment plan early in the disease
  • 9. Rheumatoid Arthritis: Treatment Principles  Confirm the diagnosis  Determine where the patient stands in the spectrum of disease  When damage begins early, start aggressive treatment early  Use the safest treatment plan that matches the aggressiveness of the disease  Monitor treatment for adverse effects  Monitor disease activity, revise Rx as needed
  • 10. Critical Elements of a Treatment Plan: Assessment • Assess current activity • Morning stiffness, synovitis, fatigue, ESR • Document the degree of damage • ROM and deformities • Joint space narrowing and erosions on x-ray • Functional status • Document extra-articular manifestations • Nodules, pulmonary fibrosis, vasculitis • Assess prior Rx responses and side effects
  • 11. Critical Elements of a Treatment Plan: Therapy • Education • Build a cooperative long-term relationship • Assistive devices • Exercise • ROM, conditioning, and strengthening exercises • Medications • Analgesic and/or anti-inflammatory • Immunosuppressive, cytotoxic, and biologic • Balance efficacy and safety with activity
  • 12. Rheumatoid Arthritis: Drug Treatment Options • NSAIDs • Symptomatic relief, improved function • No change in disease progression • Low-dose prednisone (10 mg qd) • May substitute for NSAID • Used as bridge therapy • If used long term, consider prophylactic treatment for osteoporosis • Intra-articular steroids • Useful for flares Paget. Primer on Rheum Dis. 11th edition. 1997:168.
  • 13. Rheumatoid Arthritis: Treatment Options • Disease modifying drugs (DMARDs) • Minocycline • Modest effect, may work best early • Sulfasalazine, hydroxychloroquine • Moderate effect, low cost • Intramuscular gold • Slow onset, decreases progression, rare remission • Requires close monitoring Alarcon. Rheum Dis Clin North Am. 1998;24:489–499. Paget. Primer on Rheum Dis. 11th edition. 1997:168.
  • 14. Paget. Primer on Rheum Dis. 11th edition. 1997:168. Rheumatoid Arthritis: Treatment Options (cont’d) • Immunosuppressive drugs • Methotrexate • Most effective single DMARD • Good benefit-to-risk ratio • Azathioprine • Slow onset, reasonably effective • Cyclophosphamide • Effective for vasculitis, less so for arthritis • Cyclosporine • Superior to placebo, renal toxicity
  • 15. Rheumatoid Arthritis: Treatment New Options—Combinations  Methotrexate, hydroxychloroquine, and sulfasalazine  Superior to any one or two alone for ACR 50% improvement response and maintenance of the response  Side effects no greater0 10 20 30 40 50 60 70 80 90 2-Year Outcome PercentWith50%ACRResponse Triple RX SSZ+ HCQ MTX
  • 16. Rheumatoid Arthritis: Treatment New Options—Combinations (cont’d) • Step-down prednisone with sulfasalazine and low-dose methotrexate* • Superior to sulfasalazine in early disease* • Methotrexate + hydroxychloroquine or methotrexate + cyclosporine† • May have additive beneficial effects† *Boers, et al. Lancet. 1997;350:309–318. †Stein, et al. Arth Rheum. 1997;40:1721–1723.
  • 17. Rheumatoid Arthritis: Treatment Options—New DMARDs • Leflunomide • Pyrimidine inhibitor • Effect and side effects similar to those of MTX • Etanercept • Soluble TNF receptor, blocks TNF • Rapid onset, quite effective in refractory patients in short-term trials and in combination with MTX • Injection site reactions, long-term effects unknown, expensive Rozman. J Rheumatol. 1998;53:27–32. Moreland. Rheum Dis Clin North Am. 1998;24:579–591.
  • 18. Rheumatoid Arthritis: Monitoring Treatment With DMARDs • These drugs need frequent monitoring • Blood, liver, lung, and kidney are frequent sites of adverse effects • Interval of laboratory testing varies with the drug • 4- to 8-week intervals are commonly needed • Most patients need to be seen 3 to 6 times a year
  • 19. Rheumatoid Arthritis: Adverse Effects of DMARDs Drug Hem Liver Lung Renal Infect Ca Other HCQ + - - - - - Eye SSZ + + + - - - GI Sx Gold ++ - + ++ - - Rash MTX + + ++ - ++ ? Mucositis AZA ++ + - - ++ + Pancreas PcN ++ + + ++ - - SLE, MG Cy +++ - - - +++ +++ Cystitis CSA + ++ - +++ ++ + HTN TNF* - - - - ? ? Local Lef* ++ ++ - - ? ? *Long-term data not available. Adapted from Paget. Primer on Rheum Dis. 11th edition. 1997:168.
  • 21. Rheumatoid Arthritis: Case 1  34-year-old woman with 5-year history of RA  Morning stiffness = 30 minutes  Synovitis: 1+ swelling of MCP, PIP, wrist, and MTP joints  Normal joint alignment  Rheumatoid factor positive  No erosions seen on x-rays
  • 22. Rheumatoid Arthritis: Case 1 (cont’d) • Assessment • Current activity—mild • No sign of damage after 5 years • Type 2 minimally progressive course • Treatment • NSAID + safer, less potent drugs, eg, • Hydroxychloroquine, minocycline, or sulfasalazine • Education + ROM, conditioning, and strengthening exercises
  • 23. Rheumatoid Arthritis: Case 2  34-year-old woman with 1-year history of RA  Morning stiffness = 90 minutes  Synovitis: 1+ to 2+ swelling of MCP, PIP, wrist, knee, and MTP joints  Normal joint alignment  RF positive  Small erosions of the right wrist and two MCP joints seen on x-rays
  • 24. Rheumatoid Arthritis: Case 2 (cont’d) Early erosion at the tip of the ulnar styloid
  • 25. A. Soft-tissue swelling, no erosions B. Thinning of the cortex on the radial side and minimal joint space narrowing C. Marginal erosion at the radial side of the metacarpal head with joint space narrowing How fast is joint damage progressing? Rheumatoid Arthritis: Case 2 (cont’d) ACR Clinical Slide Collection, 1997.
  • 26. Rheumatoid Arthritis: Case 2 (cont’d) • Assessment of case 2 • Moderate disease activity • Many joints involved • Clear radiologic signs of joint destruction early in disease course • Type 3 progressive course • Treatment should be more aggressive • NSAID, MTX, SSZ, and hydroxychloroquine would be a good choice
  • 27. Rheumatoid Arthritis: Case 3 • 34-year-old woman with 3-year history of RA • Morning stiffness = 3 hours • 2 to 3+ swelling of MCP, PIP, wrist, elbow, knee, and MTP joints • Ulnar deviation, swan neck deformities, decreased ROM at wrists, nodules on elbows • RF positive, x-rays show erosions of wrists and MCP joints bilaterally • Currently on low-dose prednisone + MTX, SSZ, and hydroxychloroquine
  • 28. Rheumatoid Arthritis: Case 3 (cont’d) • Assessment • Very active disease in spite of aggressive combination therapy • Evidence of extensive joint destruction • Treatment options are many • Step-down oral prednisone, 60 mg qd tapered to 10 mg qd over 5 weeks, can be used for immediate relief of symptoms • Use other cytotoxics or cyclosporine • Consider TNF inhibitor or leflunomide
  • 29. Rheumatoid Arthritis: Treatment Plan Summary • A variety of treatment options are available • Treatment plan should match • The current disease activity • The documented and anticipated pace of joint destruction • Consider a rheumatology consult to help design a treatment plan
  • 31. RA: Unknown Case 1  68-year-old woman with 3-year history of RA is squeezed into your schedule as a new patient  She presents with 4 weeks of increasing fatigue, dizziness, dyspnea, and anorexia  Her joint pain and stiffness are mild and unchanged  Managed with ibuprofen and hydroxychloroquine until 4 months ago, when a flare caused a switch to piroxicam and prednisone
  • 32. RA: Unknown Case 1 (cont’d)  Past history: Peptic ulcer 10 years ago and mild hypertension  Exam shows a thin, pale apathetic woman with Temp 98.4ºF, BP 110/65, pulse 110 bpm  Symmetrical 1+ synovitis of the wrist, MCP, PIP, and MTP joints  Exam of the heart, lungs, and abdomen is unremarkable
  • 33. RA: Unknown Case 1 (cont’d)  You are falling behind in your schedule  What system must you inquire more about today? A. Cardiovascular B. Neuropsychological C. Endocrine D. Gastrointestinal
  • 34. RA: Unknown Case 1 (cont’d) Don’t Miss It • NSAID Gastropathy is sneaky and can be fatal
  • 35. RA: Unknown Case 1 (cont’d) • Clues of impending disaster • High risk for NSAID gastropathy • Presentation suggestive of blood loss • Pale, dizzy, weak • Tachycardia, low blood pressure • No evidence of flare in RA to explain recent symptoms of increased fatigue
  • 36. Singh. Am J Med. 1998;105(suppl B):31S–38S. NSAID Gastropathy  Gastric ulcers > duodenal ulcers  No reliable warning signs  80% of serious events occur without prior symptoms  Risk of hospitalization for NSAID ulcers in RA is 2.5 to 5.5 times higher than general population
  • 37. Singh. Am J Med. 1998;105(suppl B):31S–38S. Key Point: Know the Risk Factors for NSAID Ulcers  Older age  Prior history of peptic ulcer or GI symptoms with NSAIDs  Concomitant use of prednisone  NSAID dose: More prostaglandin suppression = greater risk of serious events  Disability level: The sicker the patient the higher the risk
  • 38. Hawkey. N Engl J Med. 1998;338:727–734. NSAID Gastropathy: Treatment • Acute bleed or perforation • Stop NSAID • Endoscopy or surgery • Start omeprazole • Ulcer without bleed or perforation, and needs or wants continued NSAID • Omeprazole 20 mg qd—76% healed • Misoprostol 200 µg qid—71% healed
  • 39. NSAID Gastropathy: Prevention • Avoid the problem • Stop the NSAID and use alternative treatment • Low-dose prednisone • Acetaminophen • Nonacetylated salicylates • Use a selective cyclooxygenase-2 inhibitor
  • 40. Differential Expression of COX-1 and COX-2 Cyclooxygenase (COX) enzymes are a key step in prostaglandin production COX-1 Housekeeping most tissues stomach platelets kidney Inducible macrophages Furst. Rheum Grand Rounds. 1998;1:1. Needleman, et al. J Rheumatol. 1997;24(suppl 49):6–8. COX-2 Inducible immune system, ovary, amniotic fluid, bone, kidney, colorectal tumors Housekeeping brain, kidney
  • 41. Selective COX-2 Suppression: A Potentially Elegant Solution • Traditional NSAIDs at full therapeutic doses inhibit both enzymes • Most have greater effect on COX-1 than COX-2 • The new drugs are highly selective for COX-2 • >300-fold more effective against COX-2 • This difference allows • Major reduction in COX-2 production of proinflammatory PGs • Sparing of COX-1–produced housekeeping PGs Vane, Botting. Am J Med. 1998;104(suppl 3A):2S–8S.
  • 42. NSAID Gastropathy: Prevention • Short-term (1 to 4 weeks) clinical studies with COX-2 inhibitor in patients with OA and RA* • Significant control of arthritis symptoms • Fewer endoscopic ulcers • No effect on platelet aggregation or bleeding time • Insufficient data to determine risk of serious events or safety in high-risk populations • Celecoxib and rofecoxib have been approved; meloxicam and other selective inhibitors are currently in clinical trials *Celecoxib. Simon, et al. Arth Rheum. 1998;41:1591–1602.
  • 43. NSAID Gastropathy: Prevention (cont’d) • Counteract the problem • Misoprostol • Reduction of serious events by 40% • Results best with 200 µg qid • Side effects: diarrhea and uterine cramps • Avoid if pregnancy risk is present • Omeprazole • Recent studies show 72% to 78% reduction in all ulcers when used for primary prevention at 20 mg qd Scheiman, Isenberg. Am J Med. 1998;105(suppl 5A):32S–38S. Hawkey. Am J Med. 1998;104(suppl 3A):67S–74S.
  • 44. NSAID Gastropathy: Key Points • Keep it in mind • Know the risk factors • The best way to treat it is to prevent it • Avoid it: Use acetaminophen, salsalate, or a selective COX-2 inhibitor • Counteract it: Omeprazole or misoprostol • Antacids and H2 blockers are not the answer • May mask symptoms but do not prevent serious events
  • 45. Rheumatoid Arthritis: Unknown Case 2  You are doing a preop physical for a routine cholecystectomy on a 43-year-old woman with RA since age 20. PH includes bilateral THAs and left TKA. No other medical problems. Current meds: NSAID, low-dose prednisone, MTX, and HCQ  General physical exam normal  MS exam, extensive deformities, mild synovitis  In addition to routine tests, what test should be ordered before surgery?
  • 46. Don’t Miss It Subluxation of C1 on C2 RA can cause asymptomatic instability of the neck Manipulation under anesthesia can cause spinal cord injury
  • 47. Clues for C1-C2 Subluxation • Long-standing rheumatoid arthritis or JRA • May have NO symptoms • C2-C3 radicular pain in the neck and occiput • Spinal cord compression • Quadriparesis or paraparesis • Sphincter dysfunction • Sensory deficits • TIAs secondary to compromise of the vertebral arteries Anderson. Primer on Rheum Dis. 11th edition. 1997:161.
  • 48. Rheumatoid Arthritis: Special Considerations on Preop Exam • C1-C2 subluxation • Cricoarytenoid arthritis with adductor spasm of the vocal cords and a narrow airway • Pulmonary fibrosis • Risk for GI bleeding • Need for stress steroid coverage • Discontinue NSAIDs several days preop • Discontinue methotrexate 1 to 2 weeks preop • Cover with analgesic meds or if necessary short-term, low-dose steroid if RA flares
  • 49. Rheumatoid Arthritis: Unknown Case 3  52-year-old man with destructive RA treated with NSAID and low-dose prednisone. MTX started 4 months ago, now 15 mg/wk  Presents with 3-week history of fever, dry cough, and increasing shortness of breath  Exam: Low-grade fever, fine rales in both lungs, normal CBC and liver enzymes, low albumin, diffuse interstitial infiltrates on chest x-ray
  • 50. RA: Unknown Case 3 (cont’d)  What would you do? A. Culture, treat with antibiotic for bacterial pneumonia B. Culture, give cough suppressant for viral pneumonia and watch C. Give oral steroid for hypersensitivity pneumonitis and stop methotrexate D. Give a high-dose oral pulse of steroid and increase methotrexate for rheumatoid lung
  • 51. DMARDs Have a Dark Side Don’t Miss It DMARDs have a dark side Methotrexate may cause serious problems Lung Liver Bone marrow Be on the look out for toxicity with all the DMARDs
  • 52. Methotrexate Lung • Dry cough, shortness of breath, fever • Most often seen in the first 6 months of MTX treatment • Diffuse interstitial pattern on x-ray • Bronchoalveolar lavage may be needed to rule out infection • Acute mortality = 17%; 50% to 60% recur with retreatment, which carries the same mortality • Risk factors: older age, RA lung, prior use of DMARD, low albumin, diabetes Kremer, et al. Arth Rheum. 1997;40:1829–1837.
  • 53. Rheumatoid Arthritis: Summary • Joint damage begins early • Effective treatment should begin early in most patients • Aggressive treatment can make a difference • Assess severity of patient’s disease • Current activity • Damage • Pace
  • 54. Rheumatoid Arthritis: Summary (cont’d) • Choose a treatment plan with enough power to match the disease • If in doubt, get some help • Rheumatologists can be a bargain • New classes of drugs and biologics offer new opportunities • Do no harm • Monitor for drug toxicity—high index of suspicion and routine monitoring • Alter the treatment based on changes in disease activity

Notas do Editor

  1. 1
  2. 3
  3. 4
  4. 5
  5. 6
  6. 7
  7. 8
  8. 9
  9. 10
  10. 11
  11. 12
  12. 13
  13. 14
  14. 15
  15. 16
  16. 17
  17. 18
  18. 19
  19. 20
  20. 21
  21. 22
  22. 23
  23. 24
  24. 25
  25. 26
  26. 27
  27. 28
  28. 29
  29. 30
  30. 31
  31. 32
  32. 33
  33. 34
  34. 35
  35. 36
  36. 37
  37. 38
  38. 39
  39. 40
  40. 41
  41. 42
  42. 43
  43. 44
  44. 45
  45. 46
  46. 47
  47. 48
  48. 49
  49. 50
  50. 51
  51. 52
  52. 53
  53. 54
  54. 55
  55. 56